Expression of the Embryonic Cancer Stem Cells' Biomarkers SOX2 and OCT3/4 in Oral Leukoplakias and Squamous Cell Carcinomas: A Preliminary Study.
cancer stem cells
oct3/4
oral cancers
oral leukoplakia
sox2
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
accepted:
18
09
2023
medline:
20
10
2023
pubmed:
20
10
2023
entrez:
20
10
2023
Statut:
epublish
Résumé
Cancer stem cells (CSCs) are incriminated for initiating the process of carcinogenesis either de novo or through the transformation of oral potentially malignant disorders (OPMDs) to oral squamous cell carcinoma (OSCC). The aim of this study was to detect the expression of embryonic-type CSC markers OCT3/4 and SOX2 in OSCCs and oral leukoplakias (OLs), the most common of OPMDs. The study type is experimental, and the study design is characterized as semiquantitative research, which belongs to the branch of experimental research. The experiment was conducted in the Department of Oral Medicine/Pathology, School of Dentistry, Aristotle University of Thessaloniki, Greece. This study focuses on the semiquantitative immunohistochemical (IHC) pattern of expression of CSCs protein-biomarkers SOX2 and OCT3/4, in paraffin embedded samples of 21 OSCCs of different grades of differentiation and 30 cases of OLs with different grades of dysplasia, compared to five cases of normal oral mucosa in both terms of cells' stain positivity and intensity. Statistical analysis was performed through SPSS 2017 Pearson Chi-square and the significance level was set at 0.05 (p=0.05). The expression of the respective genes of SOX2 and OCT3/4 was studied through quantitative polymerase chain reaction (qPCR), in paraffin-embedded samples of 12 cases of OLs with mild/non dysplasia and 19 cases moderately/poorly differentiated OSCCs(n=19) and five normal mucosa using the Independent Paired T-test. The genes SOX2 and Oct3/4 were expressed in all examined cases although no statistically significant correlations among normal, OL and OSCC, were established. A nuclear/membrane staining of OCT3/4 was noticed only in three out of 21 OSCCs but in none of OLs or normal cases (without statistical significance). A characteristic nuclear staining of SOX2 was noticed in the majority of the samples, mostly in the basal and parabasal layers of the epithelium. SOX2 was significantly detected in the OSCCs group (strong positivity in 17/21) than in the OL group (30 cases, mostly mildly stained) (p-value=0.007), and the normal oral epithelium (mild stained, p=0.065). Furthermore, SOX2 was overexpressed in well differentiated OSCCs group (5/OSCCs, strongly stained) rather than in mildly dysplastic and non-dysplastic OLs samples (14/OLs, mildly stained) (p-value =0.035). The characteristic expression of SOX2 but not of OCT3/4 in OLs' and OSCCs' lesions suggests the presence of neoplastic cells with certain CSC characteristics whose implication in the early stages of oral tumorigenesis could be further evaluated. The clinical use of SOX2, as prognostic factor, requires further experimental evaluation in larger number of samples.
Identifiants
pubmed: 37859926
doi: 10.7759/cureus.45482
pmc: PMC10584277
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e45482Informations de copyright
Copyright © 2023, Zisis et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Oral Oncol. 2020 Aug;107:104799
pubmed: 32446214
Cancers (Basel). 2021 Oct 13;13(20):
pubmed: 34680271
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8
pubmed: 12629218
Front Surg. 2016 Aug 02;3:46
pubmed: 27532037
Oral Oncol. 2009 Apr-May;45(4-5):317-23
pubmed: 18674954
Cureus. 2023 May 9;15(5):e38807
pubmed: 37303447
Cancer Transl Med. 2017;3(3):87-95
pubmed: 29276782
J Appl Oral Sci. 2017 Nov-Dec;25(6):708-715
pubmed: 29211293
Cureus. 2023 Jul 28;15(7):e42619
pubmed: 37565127
J Biol Chem. 2005 Jul 1;280(26):24731-7
pubmed: 15860457
Cell Signal. 2013 May;25(5):1264-71
pubmed: 23416461
Front Oral Health. 2021 Jul 21;2:685236
pubmed: 35048028
Nature. 2006 Nov 16;444(7117):364-8
pubmed: 17093407
J Oral Maxillofac Pathol. 2019 Jan-Apr;23(1):19-27
pubmed: 31110412
PLoS One. 2014 Jan 27;9(1):e87207
pubmed: 24475251
J Oral Maxillofac Pathol. 2017 Sep-Dec;21(3):463
pubmed: 29391738
Science. 2007 Dec 21;318(5858):1917-20
pubmed: 18029452
Nature. 2006 Dec 7;444(7120):756-60
pubmed: 17051156
J Oral Pathol Med. 2008 Mar;37(3):127-33
pubmed: 18251935
J Oral Maxillofac Pathol. 2020 Jan-Apr;24(1):190
pubmed: 32508482
Nat Rev Cancer. 2018 Sep;18(9):549-561
pubmed: 29849070
BMC Cancer. 2015 Oct 19;15:730
pubmed: 26483189
Oncogene. 2019 Jul;38(27):5440-5456
pubmed: 30936460
Med Oral Patol Oral Cir Bucal. 2014 Jul 01;19(4):e386-90
pubmed: 24905952
Clin Oral Investig. 2014 Jan;18(1):199-210
pubmed: 23430339
Oral Oncol. 2015 Jan;51(1):31-9
pubmed: 25456004
Cell. 2006 Aug 25;126(4):663-76
pubmed: 16904174
Science. 2013 Feb 1;339(6119):543-8
pubmed: 23239622
Cancers (Basel). 2022 Jul 22;14(15):
pubmed: 35892847
Pathol Res Pract. 2020 Jan;216(1):152769
pubmed: 31810585
J Natl Cancer Inst. 2008 May 7;100(9):672-9
pubmed: 18445819
Stem Cells Int. 2013;2013:319489
pubmed: 23533441
J Oral Pathol Med. 2016 Feb;45(2):89-95
pubmed: 26211876
Biomed Res Int. 2020 Jul 17;2020:8573793
pubmed: 32733958
Stem Cell Reports. 2020 Feb 11;14(2):271-284
pubmed: 31928951
Am J Stem Cells. 2014 Sep 05;3(2):74-82
pubmed: 25232507
Cancers (Basel). 2019 May 02;11(5):
pubmed: 31052565
Acta Otorhinolaryngol Ital. 2020 Apr;40(2):90-98
pubmed: 32469002
J Carcinog. 2021 Sep 23;20:12
pubmed: 34729044
Cell. 2009 Jul 23;138(2):286-99
pubmed: 19632179
Cancer Sci. 2020 Nov;111(11):3985-3992
pubmed: 32888236
J Appl Oral Sci. 2013 Sep-Oct;21(5):460-7
pubmed: 24212993
Clin Cancer Res. 2008 Jul 1;14(13):4085-95
pubmed: 18593985
Cell Stem Cell. 2007 Oct 11;1(4):389-402
pubmed: 18371377
Cureus. 2023 Jun 22;15(6):e40836
pubmed: 37489188